Most clinical operations teams running continuous data review are not short on dashboards. They have too many, pulling from separate systems that never quite agree, which means the actual work of detecting a signal becomes a coordination problem before it becomes an analytical one. That is the friction CluePoints is naming directly:.
The argument, laid out in a new piece from CluePoints, is that continuous review only functions when it rests on a single body of consolidated evidence, with risk-based quality management (RBQM) as the structural foundation rather than an add-on layer. The FDA formalized the case for risk-based monitoring in guidance issued in 2013 and updated more recently, but the industry’s implementation has often meant parallel monitoring streams and separate outputs that reviewers must reconcile manually. That reconciliation is where time and signal fidelity go.
The practical implication is a consolidation argument, not a technology one. Adding a new AI capability on top of a fragmented dashboard environment produces another stream to reconcile. CluePoints, which received an investment from EQT in 2024 and has launched three AI-led review capabilities, co-developed with a top-10 pharmaceutical company, which are now generally available, is positioning RBQM as the architecture that makes those capabilities usable rather than additive noise. The distinction matters for sponsors evaluating whether to build continuous review into existing infrastructure or treat it as a separate workstream.
For clinical operations teams, the concrete question is whether their current setup produces one reviewable evidence package per site or several partial ones. If a risk signal requires pulling from three dashboards to confirm, the review is not continuous in any operationally meaningful sense. The metric worth watching is how many sources a reviewer must consult before acting on a flag. That count, more than any platform capability, determines whether continuous monitoring is real or aspirational.
Source link: https://cluepoints.com/continuous-review-needs-consolidated-evidence-and-fewer-dashboards/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
